Slide background

At the forefront of ophthalmic innovation and
leading the movement toward safer, easier to administer
treatments for ophthalmic conditions

Learn More
Slide background

Novel technologies that offer a variety of benefits
to patients and clinicians, as well as potential pharma partners.

Learn More
Slide background

A potential alternative to current delivery modalities
to overcome many of the key limitations
of existing delivery methods.

Learn More

Superior Treatment Options

EyeGate Pharma (NASDAQ: EYEG) is a late-stage specialty pharmaceutical and drug delivery company focused on developing and commercializing therapeutics and drug delivery mechanisms for treating diseases of the eye. Our technology addresses two of the most prevalent issues in ophthalmic care; the existing lack of patient adherence and patient safety. We are committed to advancing our delivery technology and therapeutic candidates with a goal of bringing new, potentially superior treatment options to patients who will most likely benefit.

Lead Compound - EGP-437

The company's lead product candidate, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, delivered directly into the ocular tissue via our proprietary EyeGate®II Delivery System. Learn More

See the EyeGate II
Drug Delivery System

Breakthrough ocular technology to change the way diseases of the eye are treated. Play Video

The EyeGate II Delivery System

Our proprietary EyeGate® II Delivery System offers a potential alternative to current ocular drug delivery methods such as eye drops and injections. Using transscleral iontophoresis the system is designed to deliver optimal quantities of drugs directly into targeted ocular tissue in both the anterior and posterior segments of the eye. Learn More